Quantum Pharma PLC Appointment of Nominated Adviser (6160Q)
December 01 2016 - 2:01AM
UK Regulatory
TIDMQP.
RNS Number : 6160Q
Quantum Pharma PLC
01 December 2016
For Immediate Release 1 December 2016
Quantum Pharma Plc
('Quantum', or the 'Company')
Appointment of Nominated Adviser
Quantum Pharma plc (AIM: QP.), the service-led niche
pharmaceutical manufacturer, developer and supplier to the health
and care sectors, announces the appointment of N+1 Singer as the
Company's nominated adviser and sole broker with immediate
effect.
- Ends -
For further information:
Quantum Pharma Plc
Ian Johnson, Chairman Tel: +44 (0) 1207
Chris Rigg, CEO and CFO 279 404
Craig Swinhoe, Group Strategic www.quantumpharmaplc.com
Projects Director and Company
Secretary
N+1 Singer
(NOMAD and Broker) Tel: +44 (0) 20
Sandy Fraser / Nick Owen / 7496 3000
James White www.n1singer.com
Media enquiries:
Buchanan
Henry Harrison-Topham / Sophie Tel: +44 (0) 20
Cowles / Steph Watson 7466 5000
quantumpharma@buchanan.uk.com www.buchanan.uk.com
Notes to Editors
Quantum Pharma Plc is a service-led, niche pharmaceutical
developer, manufacturer and supplier to the retail pharmacy,
pharmaceutical wholesaler, hospital, homecare and care home
markets. Quantum Pharma operates through three divisions: Specials,
Niche Pharmaceuticals and Medication Adherence, offering a
portfolio of innovative and complementary products and
services.
Specials comprises three business units (Quantum Pharmaceutical,
UL Medicines and Quantum Aseptics Services). This division
manufactures, procures and supplies bespoke specials; batch made
specials; aseptically prepared sterile intravenous medicines;
imported medicines and special obtain products in response to a
request from a prescriber for a bespoke medicine or special product
to optimise patient treatment. The division offers an unrivalled
and constantly expanding range of products. It has a
customer-focused, service-driven business model, which provides
shorter lead times than any of its competitors.
Niche Pharmaceuticals comprises three business units (Colonis,
Lamda and PERN Consumer Products). This division is a product
development and commercialisation business focusing on taking niche
drugs through the regulatory pathway to achieve regulated status
(licensed product or medical device). The division uses the
excellent visibility of trends in the UK pharmacy and hospital
markets gained through our Specials and Medication Adherence
divisions, to allow early identification of the market opportunity
to take products from unlicensed to licensed status. The division
has a growing portfolio and pipeline of products that fit this
unlicensed to licensed pathway, as well as complementary generic,
generic plus or medical devices intended to meet unmet patient
needs across a number of therapeutic areas.
Medication Adherence comprises two business units (Biodose(R)
and Biodose Services(R)). This division provides products and
services to enhance the likelihood of a patient adhering to a
medication regime, patient-focused homecare services and services
to pharmaceutical companies. It owns Biodose(R), the only
medication delivery system on the market that accommodates both
liquid and solid doses. Biodose Connect(TM) takes patient safety
and adherence to the next level by enabling remote monitoring of
adherence to medication regimes. The division also operates a range
of specialist patient-focused homecare services to the NHS, private
clinics and pharmaceutical companies and provides the Group with
exposure to the homecare and supported living sectors of the care
pathway, complementing the focus of the remainder of the Group.
For further information, please visit
www.quantumpharmaplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPBMBRTMBBJBLF
(END) Dow Jones Newswires
December 01, 2016 02:01 ET (07:01 GMT)
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From Apr 2024 to May 2024
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From May 2023 to May 2024